CEO John Pedersen Explains Why Urology – and Augmenix – Are Enjoying Such an “Interesting Time”

06/13/18 • 27 min

In this Medtech Talk Podcast, CEO John Pedersen explains why he chose to help Augmenix roll out its SPACEOAR implant, a hydrogel that's inserted between a patient's prostate and rectum to save healthy tissue from radiation exposure. In this talk, Pedersen discusses the rise of urology - which includes the recent acquisitions of Neotract and NxThera. He also updates listeners on Augmenix's efforts to secure reimbursement. Finally, the former Boston Scientific exec offers advice to anyone working in a global Medtech company.

Previous Episode

Medtech CEOs Herbert, Elsesser on Meeting the Challenges of Leading Companies from Start-Up to IPO

CEOs often are assigned skill sets that define their stage of specialty: start-up CEOs, commercial CEOs, etc. Two of our guests at the Medtech Conference in Minneapolis defied those definitions by taking start-ups through commercial launches and onto the public markets. In these interviews, Tim Herbert of Inspire Medical and Adam Elsesser of Penumbra talk about the challenges of leading a company from Day 1 to IPO.

Next Episode

Three Experienced Medtech CEOs Share Stories of Waging Successful Wars for Device Reimbursement

We were hoping to capture some real-world wisdom by putting three CEOs –Bill Facteau of Earlens, Bob Paulson of NxThera and John Stevens of HeartFlow –on a panel to share reimbursement war stories. Many of those attending the May 31st Medtech Conference think we got our wish.